三氧化二砷治疗中晚期原发性肝癌的近期疗效  

Term Effect of Arsenic Trioxide Treatment of Advanced Hepatocellular Carcinoma

作　　者：林志宇[1] 马闻[1] 付榆[1] 乔青[1] 宿向东[1] 

机构地区：[1]四川省乐山市人民医院,四川乐山614000

出　　处：《中国医药指南》2014年第30期28-29,共2页Guide of China Medicine

摘　　要：目的观察三氧化二砷治疗中晚期原发性肝癌的近期疗效及不良反应。方法对33例采用单药三氧化二砷10 mg/d加入生理盐水静脉滴注连续14 d为1个周期,间歇2周,至少使用2个周期。结果全组4例PR,22例NC,7例PD,客观有效率12%。临床受益率：78.8%;疼痛缓解率为82.7%,81.8%患者生存质量提高;该治疗方案不良反应主要表现为Ⅰ-Ⅱ度胃肠道反应和血液学毒性,轻度的肝功能损害。结论三氧化二砷治疗中晚期原发性肝癌有较好疗效,不良反应较小,是肝癌治疗用药的较佳选择,值得临床推广。Objective To study the clinical therapeutic effects and the side effects of arsenic trioxide（As2O3）when used to treat middle or advanced primary hepatocellular carcinoma by interventional ways. Methods 33 cases with single agent arsenic trioxide 10 mg/d and saline infusion for 14 d for 1 cycles, 2 weeks intermittent, at least 2 cycles. Results All the 4 patients with PR, 22 cases of NC, 7 cases of PD, the efficiency of 12%. Clinical benefit rate： 78.8%; pain relief rate was 82.7%, the quality of life of patients with 81.8% increase; adverse reaction of the treatment mainly Ⅰ to Ⅱ gastrointestinal reaction and hematologic toxicity, liver function impairment mild. Conclusion Arsenic trioxide in the treatment of middle or advanced primary hepatocellular carcinoma have the good curative effect, less adverse reaction, is a good choice for l hepatocellular carcinoma treatment, worthy of clinical application.

关 键 词：三氧化二砷 原发性肝癌 治疗 

分 类 号：R735.7[医药卫生—肿瘤]